Nebivolol HCL IP

Global Calcium is one of the leading manufacturers and exporters of Nebivolol HCL IP CAS no. 152520-56-4, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.

As manufacturer of Nebivolol HCL IP we hereby state the following facts about the drug:

Nebivolol is a beta-blocker and antihypertensive medication that has additional vasodilatory activity mediated by nitric oxide release. Nebivolol has yet to be linked to instances of clinically apparent liver injury.

Nebivolol is a racemic mixture of 2 enantiomers where one is a beta-adrenergic antagonist and the other acts as a cardiac stimulant without beta-adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and other beta-blockers are generally not first-line therapies as many patients are first treated with thiazide diuretics. Nebivolol was granted FDA approval on 17 December 2007.

Nebivolol is a highly cardioselective beta-blocker with antihypertensive efficacy similar to that of other beta-blockers, but with tolerability better than older agents in its class, which may permit nebivolol to be used more widely and effectively than other beta-blockers. Nebivolol's vasodilating effect, its anti-atherosclerotic effect, and its positive effects on arterial compliance suggest that it may provide more cardiovascular benefits than traditional beta-blockers, particularly in patients with isolated systolic hypertension, diabetics, black patients, and patients with known vascular disease.

Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market